Irritable bowel syndrome: the role of gut neuroendocrine peptides.
Irritable bowel syndrome (IBS) is a common chronic disorder with a prevalence ranging from 5 to 10 percent of the world's population. This condition is characterised by abdominal discomfort or pain, altered bowel habits, and often bloating and abdominal distension. IBS reduces quality of life in the same degree of impairment as major chronic diseases such as congestive heart failure and diabetes and the economic burden on the health care system and society is high. Abnormalities have been reported in the neuroendocrine peptides/amines of the stomach, small- and large intestine in patients with IBS. These abnormalities would cause disturbances in digestion, gastrointestinal motility and visceral hypersensitivity, which have been reported in patients with IBS. These abnormalities seem to contribute to the symptom development and appear to play a central role in the pathogenesis of IBS. Neuroendocrine peptides/amines are potential tools in the treatment and diagnosis of IBS. In particular, the cell density of duodenal chromogranin A expressing cells appears to be a good histopathological marker for the diagnosis of IBS with high sensitivity and specificity.
Section for Gastroenterology, Department of Medicine, Stord Helse-Fonna Hospital, Norway. magdy.el-salhy@helse-fonna.no
Magdy
M
El-Salhy
Inge
I
Seim
Lisa
L
Chopin
Doris
D
Gundersen
Jan Gunnar
JG
Hatlebakk
Trygve
T
Hausken
D006801:Humans; D043183:Irritable Bowel Syndrome / Q000175:diagnosis / Q000503:physiopathology*; D009490:Neurosecretory Systems / Q000378:metabolism*; D010455:Peptides / Q000378:metabolism / Q000502:physiology*
D010455:Peptides